Cellular and Molecular Mechanisms of Prion Disease.
Sigurdson CJ, Bartz JC, Glatzel M.
Annu Rev Pathol. 2019 Jan 24;14:497-516. doi: 10.1146/annurev-pathmechdis-012418-013109. Epub 2018 Oct 24.
Prion Disease.
Baldwin KJ, Correll CM.
Semin Neurol. 2019 Aug;39(4):428-439. doi: 10.1055/s-0039-1687841. Epub 2019 Sep 18.
Prion disease modelled in Drosophila.
Bujdoso R, Smith A, Fleck O, Spiropoulos J, Andréoletti O, Thackray AM.
Cell Tissue Res. 2023 Apr;392(1):47-62. doi: 10.1007/s00441-022-03586-0. Epub 2022 Jan 29.
Neuroinflammation in Prion Disease.
Li B, Chen M, Zhu C.
Int J Mol Sci. 2021 Feb 23;22(4):2196. doi: 10.3390/ijms22042196.
Human prion disease: molecular pathogenesis, and possible therapeutic targets and strategies.
Baiardi S, Mammana A, Capellari S, Parchi P.
Expert Opin Ther Targets. 2023 Jul-Dec;27(12):1271-1284. doi: 10.1080/14728222.2023.2199923. Epub 2023 Jun 19.
Prion Diseases.
Geschwind MD.
Continuum (Minneap Minn). 2015 Dec;21(6 Neuroinfectious Disease):1612-38. doi: 10.1212/CON.0000000000000251.
Genetic counseling for prion disease: Updates and best practices.
Goldman JS, Vallabh SM.
Genet Med. 2022 Oct;24(10):1993-2003. doi: 10.1016/j.gim.2022.06.003. Epub 2022 Jul 12.
Therapeutic development of polymers for prion disease.
Teruya K, Doh-Ura K.
Cell Tissue Res. 2023 Apr;392(1):349-365. doi: 10.1007/s00441-022-03604-1. Epub 2022 Mar 21.
Clinical diagnosis of human prion disease.
Knight R.
Prog Mol Biol Transl Sci. 2020;175:1-18. doi: 10.1016/bs.pmbts.2020.07.006. Epub 2020 Aug 24.
Towards a treatment for genetic prion disease: trials and biomarkers.
Vallabh SM, Minikel EV, Schreiber SL, Lander ES.
Lancet Neurol. 2020 Apr;19(4):361-368. doi: 10.1016/S1474-4422(19)30403-X. Epub 2020 Mar 18.
